ClinicalTrials.gg
RecruitingNCT06807359Updated May 1, 2026

Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System

A Phase 1/2 interventional study of Photodynamic Therapy (PDT) and Verteporfin Injection in Prostate Cancer, sponsored by SpectraCure AB. Recruiting at 3 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by SpectraCure AB · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 333 studies in Prostatic Neoplasms with a site in Germany — 71 open to participants now, 117 under way, 36 of them phase 3. Prostatic Neoplasms · Germany.

Planned enrollment
245th of 269
43 · median 278
Started
2025
with 24 others
Phase 1/2
13 of 333
8 open now
Primary completion
2028-01
later than 69 of 116 live
Registered
291st of 333
by date

Among the 333 studies in Prostatic Neoplasms with a site in Germany, this one is the 245th largest by planned enrollment of the 269 interventional ones that give a count, is one of 25 that started in 2025, is one of 13 in phase 1/2, reaches primary completion later than 69 of the 116 other live ones, and was the 291st registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

71 of the 333 studies in Prostatic Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

66 more — sign in →

All 71 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 333 studies in Prostatic Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

The goal of this study is to obtain safety data, establish dose parameters, and effectiveness of treatment for the SpectraCure P18 System with IDOSE®, together with verteporfin for injection (VFI) as photosensitizer, for the treatment of primary localized prostate cancer.

The study will be divided into two parts, with Phase I, dose-escalation, to study safety and establish an effective light dose, followed by Phase II, cohort expansion, to evaluate clinical efficacy and confirm safety/tolerability. The subjects will be followed for a period of 18 months to determine the primary outcome. The long-term follow-up is an additional 18 months, i.e. a total of 36 months.

Interstitial Photodynamic Therapy (PDT) will be performed during general anesthesia. Optical fibers will be inserted into the prostate with a transperineal approach using transrectal ultrasound guidance. The intent is to deliver an adequate light dose throughout the prostate. Subjects will receive VFI intravenously, approximately 60-90 minutes prior to light delivery.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects ≥ 18 years.
  2. confirmed organ-confined adenocarcinoma of the prostate cancer diagnosed within the last 9 months. Including subjects on active surveillance with evidence of disease progression and a prostate not older than 9 months.

    a. This prostate biopsy should be targeted and systematic (transperineal or transrectal are both acceptable) and include both systematic sampling with a minimum of 8 cores (4 right, 4 left) as well as MRI fusion targeted cores. The minimum number of targeted cores is two (2) but more may be included at the discretion of the surgeon.

  3. Gleason Score 7 (3+4 or 4+3).
  4. PSA ≤ 15 ng/mL.
  5. Lesion volume on mpMRI \< 1.5 cm3.
  6. Adequate stage imaging such as pelvic CT/MRI/PET scan within the last 6 months confirming localized cancer.

    - Bone scan is optional if PSA \< 10 ng/mL.

  7. Treatment target volume \<50 cm3 defined by TRUS or MRI.
  8. (ECOG) performance status of 0 or 1.
  9. Expected survival ≥ 36 months.
  10. Sufficient bone marrow reserve as indicated by; granulocyte count ≥ 1500/mm3, count ≥ 100,000/mm3.
  11. Adequate renal function as defined by creatinine ≤ 1.5 mg /dl.
  12. Adequate hepatic function, based on a total ≤ 1.5 mg/dl, serum glutamate-oxaloacetate transaminase () ≤ 3 times the , and alanine transaminase (ALT) ≤ 3 times the upper limit of normal.
  13. Signed .

Exclusion criteria

Exclusion Criteria:

  1. Evidence of locally advanced, regional pelvic lymph node , or metastatic disease.
  2. Any suspicious for, probable, or definite extracapsular extension on pretreatment MRI
  3. Contralateral PIRADS 4/5 lesion (even if negative targeted )
  4. High volume GG1 disease in the contralateral prostate, outside of the ablation zone. High volume is defined as >1 core of GG1 with a linear amount of carcinoma >6mm.
  5. Prior radical surgery for carcinoma of the prostate, prior pelvic radiation, prior TURP, prior cryosurgery of the prostate.
  6. Prior treatment with any form of brachytherapy.
  7. Previous androgen deprivation therapy (ADT) or chemotherapy for prostate cancer.
  8. Prior or current bleeding diathesis.
  9. Tumors known to be eroding into a major blood vessel in or adjacent to the illumination site.
  10. Use of Alpha-reductase inhibitors (ARIs) within 90 days of enrolment.
  11. Any serious active or co-morbid medical conditions, laboratory abnormality, psychiatric illness, active or uncontrolled infections, or serious illnesses or medical conditions that would prevent the patient from participating or to be managed according to the protocol (according to investigator's decision).
  12. Mental incapacity or psychiatric illness that would interfere with the subject's ability to understand and give or to complete follow-up visits according to the judgement of the investigator.
  13. for photosensitizer including:

    1. Porphyria or other diseases exacerbated by light.
    2. Known to verteporfin for injection (VFI) or to any of the .
    3. Known allergies to porphyrins.
  14. On-going therapy with a photosensitizing agent.
  15. Enrolment in another therapeutic clinical study within 3 month prior to enrolment and throughout the study.
  16. Contraindication for MRI/Gadolinium contrast such as: implants, hip prosthesis, severe renal impairment ( [GFR] \<30 mL/min/1.73m2), or previous contrast reactions.
  17. Has known hypersensitivity to pancuronium bromide, atricurium or cisatricurium
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
43 participants (estimated)

Study arms

  • Experimental
    PDT with VFI

    Interstitial Photodynamic Therapy (PDT) and Verteporfin for Injection (VFI)

    Device: Photodynamic Therapy (PDT) · Drug: Verteporfin Injection

Interventions

  • DevicePhotodynamic Therapy (PDT)

    The PDT treatment is provided with the SpectraCure P18 laser light delivery system. PDT will be performed during general anesthesia. Optical fibers will be inserted into the prostate with a transperineal approach using transrectal ultrasound guidance. The intent is to deliver an adequate light dose throughout the prostate. Subjects will receive VFI intravenously, approximately 60-90 minutes prior to light delivery. The photosensitizer is activated with light of a specific wavelength that is delivered to the tumor via optical fibers. The activated photosensitizer reacts with oxygen to form highly toxic radicals which induce cell death in the tumour. * Phase 1: Light dose escalation. Three subjects will be treated per dose level (20 - 40 J/cm2). If no dose-limiting toxicities occur, dose will be escalated (20 - 40 J/cm2) until the Recommended Phase 2 Dose (RPD2) is established. * Phase 2: Cohort expansion with the RPD2.

  • Verteporfin for Injection (VFI), photosensitizing drug, will be administered intravenously at a dose of 15 mg/m2 body surface area.

    Also known as: Visudyne

06

What researchers measure

Primary outcomes

  1. Safety of treatment

    Number of participants with treatment related adverse events as assessed by CTCAE v5.0 related to therapy per protocol. Dose limiting toxicities are defined as grade 3 non-hematologic or grade 4 hematologic toxicities that are possibly, probably or definitely related to PDT.

    Time frame: Within 4 weeks of treatment in each cohort.

  2. Safety - Damage to the periprostatic tissue mediated by PDT

    Potential damage to the periprostatic tissue will be evaluated by contrast-enhanced and not-contrast enhanced MRI.

    Time frame: 5-9 days following PDT

  3. Treatment efficacy

    Percentage of subjects with negative in-field biopsies (histopathologically tumor-free)

    Time frame: 6 and 18 months post PDT

Secondary outcomes

  1. Adequacy of effectiveness

    Extent of quantifiable treatment effect in the prostate evaluated by MRI to determine the extent of necrosis in the prostate

    Time frame: Within 1 week following PDT

  2. Treatment efficacy

    Rate of negative in-field biopsy as defined by the Delphi consensus criterion (≤ 3 mm of Gleason ≤ 6 disease in any biopsy core is insignificant).

    Time frame: 6 and 18 months post PDT

  3. Device performance

    Light dose coverage \>90% of the target volume; evaluated by dose-volume histograms in \>80% of subjects

    Time frame: Day of PDT

  4. Percentage of subjects with biochemical failure

    Failure defined as a rise in PSA level of 2.0 ng/mL or more, over and above the nadir

    Time frame: 6 and 10 weeks, 6, 18, 24 and 36 months post PDT

  5. Percentage of subjects with extra prostatic or distant disease

    Remaining localized tumour will be evaluated by MRI

    Time frame: 6 and 18 months post PDT

07

Study locations

3 of 3 sites recruiting
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • Jonathan Fainberg, MD, MPH · Principal investigator
  • Klinik für Urologie, Universitätsklinikum Köln
    Cologne, 50937, Germany
    Recruiting
    • Axel Heidenreich, Prof. Dr. med. · Principal investigator
  • Klinik und Poliklinik für Urologie, Universitätsmedizin Rostock
    Rostock, Germany
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jan 2028, 36 months after the start.

Of 97 industry-sponsored phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35. This study's planned 36 months is below that.

Counting every sponsor, half of 211 studies reached it within 61 months; a quarter within 30 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2025
First posted
Feb 4, 2025
StartActual
Jan 6, 2025
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2029
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06807359
Lead sponsor
SpectraCure AB
Responsible party
Sponsor
First posted
Feb 4, 2025
Start date
Jan 6, 2025
Primary completion
Jan 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
May 1, 2026

Study contacts

Kristina Holst
Contact
clinical@spectracure.com
+46708233630
Jonathan Fainberg, MD, MPH
principal investigator · Memorial Sloan Kettering Cancer Center, New York, United States

Oversight

FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Verteporfin

Start the discussion